SPRB logo

SPRB
Spruce Biosciences Inc

5,124
Mkt Cap
$83.59M
Volume
60,800.00
52W High
$240.00
52W Low
$4.28
PE Ratio
-0.87
SPRB Fundamentals
Price
$73.70
Prev Close
$78.09
Open
$81.22
50D MA
$96.00
Beta
1.08
Avg. Volume
82,273.86
EPS (Annual)
-$96.39
P/B
7.71
Rev/Employee
$233,857.14
Loading...
Loading...
News
all
press releases
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet...
Business Wire·17h ago
News Placeholder
More News
News Placeholder
Spruce Biosciences (NASDAQ:SPRB) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen lowered Spruce Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·13d ago
News Placeholder
Equities Analysts Offer Predictions for SPRB FY2025 Earnings
Spruce Biosciences, Inc. (NASDAQ:SPRB - Free Report) - Equities researchers at HC Wainwright issued their FY2025 EPS estimates for Spruce Biosciences in a report released on Monday, December 22nd. HC...
MarketBeat·16d ago
News Placeholder
HC Wainwright Reaffirms Buy Rating for Spruce Biosciences (NASDAQ:SPRB)
HC Wainwright reiterated a "buy" rating and set a $220.00 price objective on shares of Spruce Biosciences in a research note on Monday...
MarketBeat·18d ago
News Placeholder
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the company...
MarketBeat·23d ago
News Placeholder
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·25d ago
News Placeholder
Wall Street Zen Upgrades Spruce Biosciences (NASDAQ:SPRB) to Hold
Wall Street Zen upgraded Spruce Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·1mo ago
News Placeholder
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Outperform" at Leerink Partners
Leerink Partners raised Spruce Biosciences from a "market perform" rating to an "outperform" rating and set a $160.00 price target for the company in a research report on Wednesday...
MarketBeat·1mo ago
News Placeholder
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Recommendation of "Hold" from Brokerages
Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) have been assigned a consensus rating of "Hold" from the ten ratings firms that are covering the firm, Marketbeat.com reports. One...
MarketBeat·2mo ago
News Placeholder
Citizens Jmp Forecasts Strong Price Appreciation for Spruce Biosciences (NASDAQ:SPRB) Stock
Citizens Jmp raised their price target on Spruce Biosciences from $254.00 to $259.00 and gave the stock a "market outperform" rating in a research report on Tuesday...
MarketBeat·2mo ago
<
1
2
...
>

Latest SPRB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.